Diabetes Management Market: Information by Device Type (Diagnostic Devices, Monitoring Devices) and Therapeutics Type (Injectables and Oral), and Region — Forecast till 2029

Mar 28, 2020   Market Overview Diabetes is recognized as one of the most prevalent chronic diseases across the globe. As per the International Diabetes Federation, 1 in every 11 adults aged 20–79 years are living with diabetes, which is about 463 million. To address the situation, many public and private organizations are implementing different strategies for better management of diabetes, which includes intervention programs, such as lifestyle modification, promotional and educational campaigns, clinic...
Request Free Sample Report

Table Of Content

TABLE OF CONTENTS

1          Introduction

1.1       Market Definition

1.2       Market Scope

2          Research Methodology

2.1       Primary Research

2.2       Research Methodology

2.3       Assumptions & Exclusions

2.4       Secondary Data Sources

3          Market Overview

3.1       Report Segmentation & Scope

3.2       Value Chain Analysis: Diabetes Management Market

3.3       Key Market Trends

3.3.1   Drivers

3.3.2   Restraints

3.3.3   Opportunities

3.4       Porter’s Five Forces Analysis

3.4.1   Bargaining Power of Suppliers

3.4.2   Bargaining Power of Buyers

3.4.3   Threat of Substitution

3.4.4   Threat of New Entrants

3.4.5   Competitive Rivalry

3.5       Market Share Analysis

3.6       Top Winning Strategies

3.7       Technology Overview

4          Device Type Overview

4.1       Introduction

4.1.1   Market Size & Forecast (Value)

4.2       Monitoring Devices

4.2.1   Market Size & Forecast (Value)

4.3       Diagnostic Devices

4.3.1   Market Size & Forecast (Value)

4.4       Insulin Delivery Devices

4.4.1   Market Size & Forecast (Value)

4.5       Other Devices

4.5.1   Market Size & Forecast (Value)

5          Therapeutics Overview

5.1       Introduction

5.1.1   Market Size & Forecast (Value)

5.2       InjecTABLEs

5.2.1   Market Size & Forecast (Value)

5.3       Oral

5.3.1   Market Size & Forecast (Value)

6          Regional Overview

6.1      Introduction

6.1.1   Market Size & Forecast (Value)

6.2      America

6.2.1   North America

6.2.1.1 U.S.

6.2.1.1.1         By Device Type

6.2.1.1.2         By Therapeutics

6.2.1.2 Canada

6.2.1.2.1         By Device Type

6.2.1.2.2         By Therapeutics

6.2.1.3 Mexico

6.2.1.3.1         By Device Type

6.2.1.3.2         By Therapeutics

6.2.2   Central, South America and Caribbean

6.2.2.1      By Device Type

6.2.2.2      By Therapeutics

6.2.2.2.1   Brazil

6.2.2.2.1.1      By Device Type

6.2.2.2.1.2      By Therapeutics

6.2.2.2.2   Argentina

6.2.2.2.2.1      By Device Type

6.2.2.2.2.2      By Therapeutics

6.2.2.2.3   Rest of South America

6.2.2.2.3.1      By Device Type

6.2.2.2.3.2      By Therapeutics

6.3      Europe

6.3.1   Market Size & Forecast (Value)

6.3.2   Western Europe

6.3.2.1 U.K

6.3.2.1.1         By Device Type

6.3.2.1.2         By Therapeutics

6.3.2.2 Germany

6.3.2.2.1         By Device Type

6.3.2.2.2         By Therapeutics

6.3.2.3 France

6.3.2.3.1         By Device Type

6.3.2.3.2         By Therapeutics

6.3.2.4 Spain

6.3.2.4.1         By Device Type

6.3.2.4.2         By Therapeutics

6.3.2.5 Italy

6.3.2.5.1         By Device Type

6.3.2.5.2         By Therapeutics

6.3.2.6 Rest of Western Europe

6.3.2.6.1         By Device Type

6.3.2.6.2         By Therapeutics

6.3.3   Eastern Europe

6.3.3.1  By Device Type

6.3.3.2  By Therapeutics

6.4      Asia Pacific

6.4.1   Market Size & Forecast (Value)

6.4.2   Japan

6.4.2.1            By Device Type

6.4.2.2            By Therapeutics

6.4.3   China

6.4.3.1            By Device Type

6.4.3.2            By Therapeutics

6.4.4   Australia

6.4.4.1            By Device Type

6.4.4.2            By Therapeutics

6.4.5   India

6.4.5.1            By Device Type

6.4.5.2            By Therapeutics

6.4.6   South Korea

6.4.6.1            By Device Type

6.4.6.2            By Therapeutics

6.4.7   Rest of Asia-Pacific

6.4.7.1            By Device Type

6.4.7.2            By Therapeutics

6.5      Middle East & Africa

6.5.1   The Middle East

6.5.1.1            Market Size & Forecast (Value)

6.5.1.2 Saudi Arabia

6.5.1.2.1         By Device Type

6.5.1.2.2         By Therapeutics

6.5.1.3 UAE

6.5.1.3.1         By Device Type

6.5.1.3.2         By Therapeutics

6.5.1.4 Qatar

6.5.1.4.1         By Device Type

6.5.1.4.2         By Therapeutics

6.5.2   The Africa

6.5.2.1            Market Size & Forecast (Value)

7          Company Profile

7.1      Abbott Laboratories

7.1.1   Company Overview

7.1.2   Financial Performance

7.1.3   Recent Developments

7.1.4   Product Portfolio

7.2      Bayer AG.

7.2.1   Company Overview

7.2.2   Financial Performance

7.2.3   Recent Developments

7.2.4   Product Portfolio

7.3      Bristol-Myers Squibb

7.3.1   Company Overview

7.3.2   Financial Performance

7.3.3   Recent Developments

7.3.4   Product Portfolio

7.4      Eli Lilly and Co.

7.4.1   Company Overview

7.4.2   Financial Performance

7.4.3   Recent Developments

7.4.4   Product Portfolio

7.5      Sanofi

7.5.1   Company Overview

7.5.2   Financial Performance

7.5.3   Recent Developments

7.5.4   Product Portfolio

7.6      Dexcom

7.6.1   Company Overview

7.6.2   Financial Performance

7.6.3   Recent Developments

7.6.4   Product Portfolio

7.7      Medtronic

7.7.1   Company Overview

7.7.2   Financial Performance

7.7.3   Recent Developments

7.7.4   Product Portfolio

7.8      Novo Nordisk A/S

7.8.1   Company Overview

7.8.2   Financial Performance

7.8.3   Recent Developments

7.8.4   Product Portfolio

8          Conclusion & Recommendations

9          Acronyms & Abbreviations